title: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
abstract: Prediction of recurrence remains a challenge in histopathological benign/grade I tumors. Osteopontin (OPN) plays important roles in tumorigenesis, invasion, and metastasis of several human cancers. In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas. Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II). Cytoplasmic OPN staining was evaluated by means of immunohistochemistry (IHC) score and by use of the Allred-8-unit system. We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN. Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001). An OPN Allred score between 0 and 3 was associated with a recurrence-free time of more than 25 months. In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time. We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas. Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
authors.affiliation: Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center 325, Sec. 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan, ROC.
authors.forename: Kuan-Yin
authors.initials: KY
authors.lastname: Tseng
authors.forename: Min-Huey
authors.initials: MH
authors.lastname: Chung
authors.forename: Huey-Kang
authors.initials: HK
authors.lastname: Sytwu
authors.forename: Horng-Mo
authors.initials: HM
authors.lastname: Lee
authors.forename: Kuan-Yu
authors.initials: KY
authors.lastname: Chen
authors.forename: Chen
authors.initials: C
authors.lastname: Chang
authors.forename: Chih-Kung
authors.initials: CK
authors.lastname: Lin
authors.forename: Che-Hung
authors.initials: CH
authors.lastname: Yen
authors.forename: Jia-Hong
authors.initials: JH
authors.lastname: Chen
authors.forename: Gu-Jiun
authors.initials: GJ
authors.lastname: Lin
authors.forename: Hsin-I
authors.initials: HI
authors.lastname: Ma
authors.forename: Yi-Shian
authors.initials: YS
authors.lastname: Yeh
authors.forename: Da-Tong
authors.initials: DT
authors.lastname: Ju
authors.forename: Ming-Ying
authors.initials: MY
authors.lastname: Liu
authors.forename: Dueng-Yuan
authors.initials: DY
authors.lastname: Hueng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008577:Meningeal Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D008579:Meningioma / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology*; D053495:Osteopontin / Q000096:biosynthesis*; D046888:Tissue Array Analysis; D014944:World Health Organization; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C506895:SPP1 protein, human; D053495:Osteopontin